IL117159A0 - Immunotherapeutic methods and compositions for screening prognosis and therapy - Google Patents

Immunotherapeutic methods and compositions for screening prognosis and therapy

Info

Publication number
IL117159A0
IL117159A0 IL11715996A IL11715996A IL117159A0 IL 117159 A0 IL117159 A0 IL 117159A0 IL 11715996 A IL11715996 A IL 11715996A IL 11715996 A IL11715996 A IL 11715996A IL 117159 A0 IL117159 A0 IL 117159A0
Authority
IL
Israel
Prior art keywords
therapy
compositions
immunotherapeutic methods
prognosis
screening
Prior art date
Application number
IL11715996A
Original Assignee
Immunotherapy Inc
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunotherapy Inc, Yeda Res & Dev filed Critical Immunotherapy Inc
Publication of IL117159A0 publication Critical patent/IL117159A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
IL11715996A 1995-02-17 1996-02-16 Immunotherapeutic methods and compositions for screening prognosis and therapy IL117159A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39255395A 1995-02-17 1995-02-17
US48185795A 1995-06-07 1995-06-07

Publications (1)

Publication Number Publication Date
IL117159A0 true IL117159A0 (en) 1996-06-18

Family

ID=27013925

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11715996A IL117159A0 (en) 1995-02-17 1996-02-16 Immunotherapeutic methods and compositions for screening prognosis and therapy

Country Status (3)

Country Link
AU (1) AU4977896A (en)
IL (1) IL117159A0 (en)
WO (1) WO1996025664A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997033612A1 (en) * 1996-03-15 1997-09-18 Immunotherapy, Inc. Dialdehydes as immunostimulatory adjuvants and cross-linkers for producing immunogenic preparations and generating pressure and cross-link treated cells for enhancing and augmenting the immune response against cancers, tumors and pathogenic diseases
GB9706957D0 (en) 1997-04-05 1997-05-21 Smithkline Beecham Plc Formulation
AU1533099A (en) * 1998-08-25 2000-03-14 Immune Response Corporation, The Methods for evaluating immune function
GB9820525D0 (en) 1998-09-21 1998-11-11 Allergy Therapeutics Ltd Formulation
GB0000891D0 (en) * 2000-01-14 2000-03-08 Allergy Therapeutics Ltd Formulation
US20070154399A1 (en) * 2000-10-27 2007-07-05 Hadden John W Immunotherapy for immune suppressed patients
EP1777523A1 (en) 2005-10-19 2007-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method
EP2073011A1 (en) * 2007-12-20 2009-06-24 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Means and methods of processing biological samples
KR102584927B1 (en) * 2021-12-22 2023-10-06 씨제이제일제당 (주) Antiviral composition comprising nucleoside analogues derived from nucleic acid or pharmaceutically acceptable salt thereof
WO2023121362A1 (en) * 2021-12-22 2023-06-29 씨제이제일제당 (주) Antiviral composition comprising nucleoside analogues derived from nucleic acid and pharmaceutically acceptable salt thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4931275A (en) * 1985-12-02 1990-06-05 Yeda Research & Development Co., Ltd. Anti-tumor vaccines and their preparation
EP0615758B1 (en) * 1988-05-24 1999-09-22 Yeda Research And Development Co. Ltd. Anti-tumor vaccines
IT1264516B1 (en) * 1993-05-31 1996-09-24 Biotop Sas Di Rita Cassarin IMMORTALIZED DENDRITIC CELLS
US5583713A (en) * 1994-07-22 1996-12-10 Analog Devices, Inc. Pipelined demodulation and ADC conversion scheme for disk drive servo system

Also Published As

Publication number Publication date
WO1996025664A1 (en) 1996-08-22
AU4977896A (en) 1996-09-04

Similar Documents

Publication Publication Date Title
EP0825878A4 (en) Composition and method for tumor imaging
AU3628795A (en) Accelerator-base methods and apparatus for measurement-while-drilling
HUP9600707A3 (en) Feather fastening cover and method for making such feather fastening
EP0876145A4 (en) Taxane composition and method
EP0851759A4 (en) Compounds and methods
AU2582195A (en) Method of detecting cancer involving fragments of cytokeratin 18 and corresponding antibodies
GB9504495D0 (en) Method and composition
GB2338219B (en) Escape chutes
AUPN514395A0 (en) Screening apparatus
AU7388796A (en) Improved spiral binding method and apparatus
HK1120494A1 (en) Novel compounds and methods for synthesis and therapy
IL117159A0 (en) Immunotherapeutic methods and compositions for screening prognosis and therapy
GB2302515B (en) Blast apparatus
GB9522101D0 (en) Blast attenuation
GB9505090D0 (en) Improved escape chute
EP0786084A4 (en) Method for screening compositions
EP0749122A3 (en) Disc apparatus
GB9609156D0 (en) Polyurethane compositions and method
GB9525703D0 (en) Screening method
GB2308511B (en) Screening can
AU696992C (en) Screening apparatus
GB2303563B (en) Screening apparatus
AU7659496A (en) Screening method
ZA961238B (en) Immunotherapy screening prognosis and treatment methods and compositions
GB2300130B (en) Screening apparatus